Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSH | P09668 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494465 | 0.87 | MEN1 (0.43) | MEN1KMT2ACTSBCTSKCTSL | |
| SCHEMBL21374326 | 0.81 | MEN1 (0.49) | MEN1KMT2AKDM4C | |
| SCHEMBL21886901 | 0.79 | MEN1 (0.49) | MEN1KMT2AKDM4C | |
| SCHEMBL21326189 | 0.76 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL18614980 | 0.75 | MEN1 (0.41) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL22494487 | 0.73 | MEN1 (0.37) | MEN1KMT2AL3MBTL1P2RX3KDM4C | |
| SCHEMBL22504269 | 0.70 | KMT2A (0.52) | MEN1KMT2AKDM4C | |
| SCHEMBL9308239 | 0.67 | MEN1 (0.49) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL2967740 | 0.67 | MEN1 (0.45) | MEN1KMT2AKDM4C | |
| SCHEMBL9705177 | 0.67 | MEN1 (0.54) | MEN1KMT2AL3MBTL1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315745-B | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3728262-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-11440915-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3728262-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111315745-A | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | MEN1 998/4885KMT2A 2045/4885CTSB 1151/4885 |
| US-11440915-B2 | Triazolo-azepine derivatives | HUWE1, PSEN1, UPF1 | MEN1 868/4885KMT2A 1856/4885CTSB 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.